37669-64-0

Usage

Uses

Used in Pharmaceutical Industry:
(5-BROMO-PYRIDIN-3-YL)-METHANOL is used as a building block for the synthesis of various pharmaceuticals, leveraging its reactivity and the presence of the bromine atom and hydroxymethyl group to create diverse medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, (5-BROMO-PYRIDIN-3-YL)-METHANOL serves as a key component in the development of new agrochemicals, contributing to the creation of innovative products for crop protection and enhancement of agricultural yields.
Used in Organic Synthesis:
(5-BROMO-PYRIDIN-3-YL)-METHANOL is utilized as a reagent in organic synthesis, where its functional groups facilitate a broad spectrum of chemical reactions, leading to the formation of a variety of organic compounds.
Used as a Precursor for Functionalized Heterocycles:
(5-BROMO-PYRIDIN-3-YL)-METHANOL also acts as a precursor for the preparation of functionalized heterocycles, which are important in various chemical and biological applications due to their unique properties and potential for further modification.

InChI:InChI=1/C6H6BrNO/c7-6-1-5(4-9)2-8-3-6/h1-3,9H,4H2

Upstream product

• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 20986-40-7 ethyl 5-bromo-3-pyridinecarboxylate 
• 39620-02-5 5-bromonicotinoyl chloride 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 908864-98-2 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine 
• 27828-71-3 5-hydroxynicotinic acid 
• 22620-36-6 3-bromo-5-(hydroxymethyl)pyridine hydrochloride 
• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 20260-53-1 pyridine-3-carbonyl chloride hydrochloride 

Downstream Products

• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 97000-22-1 3-<(benzyloxy)methyl>-5-bromopyridine 
• 153607-77-3 3-Bromo-5-(tert-butyl-diphenyl-silanyloxymethyl)-pyridine 
• 135124-71-9 5-(hydroxymethyl)pyridine-3-carbonitrile 
• 393861-00-2 3-(hydroxymethyl)-5-(2-thiophene)pyridine 
• 152351-91-2 3-bromo-5-(tert-butyldimethylsilanyloxymethyl)pyridine 
• 173999-17-2 3-bromo-5-(methoxymethyl)pyridine 
• 145743-85-7 5-bromo-3-(bromomethyl)pyridine 
• 120277-69-2 5-bromo-pyridin-3-ylmethyl chloride 
• 135124-70-8 (5-bromo-3-pyridinyl)methylamine 
• 222551-22-6 3-(p-fluorophenyl)-5-hydroxymethyl-pyridine 
• 98664-62-1 (5-ethylpyridin-3-yl)methanol 
• 219660-71-6 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione 
• 1035234-78-6 3-bromo-5-{[(4-methoxybenzyl)oxy]methyl}pyridine 

Relevant academic research and scientific papers

Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker

Neuronal nitric oxide synthase (nNOS) is an important therapeutic target for the treatment of various neurodegenerative disorders. A major challenge in the design of nNOS inhibitors focuses on potency in humans and selectivity over other NOS isoforms. Here we report potent and selective human nNOS inhibitors based on the 2-aminopyridine scaffold with a central pyridine linker. Compound 14j, the most promising inhibitor in this study, exhibits excellent potency for rat nNOS (Ki = 16 nM) with 828-fold n/e and 118-fold n/i selectivity with a Ki value of 13 nM against human nNOS with 1761-fold human n/e selectivity. Compound 14j also displayed good metabolic stability in human liver microsomes, low plasma protein binding, and minimal binding to cytochromes P450 (CYPs), although it had little to no Caco-2 permeability.

A Modular Synthesis of Teraryl-Based α-Helix Mimetics, Part 4: Core Fragments with Two Halide Leaving Groups Featuring Side Chains of Proteinogenic Amino Acids

Teraryl-based α-helix mimetics have proven to be useful compounds for the inhibition of protein-protein interactions (PPI). We have developed a modular and flexible approach for the synthesis of teraryl-based α-helix mimetics using a benzene core unit featuring two halide leaving groups of differentiated reactivity in the Pd-catalyzed cross-coupling used for teraryl assembly. The use of para-bromo iodoarene core fragments resolved the issue of hydrolysis during cross-coupling that was observed when using triflate as a leaving group. We report a complete set of para-bromoiodoarene core fragments decorated with side chains of all proteinogenic amino acids relevant for PPI (Ala, Arg, Asn, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp, Tyr and Val). In order to be compatible with general cross-coupling conditions, some of the nucleophilic side chains had to be provided in a protected form to serve as stable building blocks.

A Modular Synthesis of Teraryl-Based α-Helix Mimetics, Part 5: A Complete Set of Pyridine Boronic Acid Pinacol Esters Featuring Side Chains of Proteinogenic Amino Acids

Teraryl-based α-helix mimetics have proven to be useful compounds for the inhibition of protein-protein interactions (PPI). We have developed a modular and flexible approach for the synthesis of teraryl-based α-helix mimetics using pyridine containing boronic acid building blocks to increase the water solubility. Following our initial publication in which we have introduced the methodology in combination with sequential Pd-catalyzed cross-coupling for teraryl assembly, we can now report a complete set of pyridine based boronic acid building blocks decorated with side chains of all proteinogenic amino acids relevant for PPI (Ala, Arg, Asn, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp, Tyr, Val) to complement the core fragment set. For a representative set of teraryls we have studied the influence of the pyridine rings on the solubility of the assembled oligoarenes.

Novel biphenyl derivative as well as preparation method and medical application thereof

The invention relates to the field of medicinal chemistry, and discloses biphenyl derivatives with PD-1/PD-L1 inhibitory activity as well as a preparation method and application of the biphenyl derivatives. The invention further discloses a composition containing the biphenyl derivative with the PD-1/PD-L1 inhibitory activity or the pharmaceutically acceptable salt of the biphenyl derivative and a pharmaceutically acceptable carrier of the biphenyl derivative, and application of the biphenyl derivative in preparation of a PD-1/PD-L1 inhibitor. The compound can be used for treating tumors.

Reaction of Diisobutylaluminum Borohydride, a Binary Hydride, with Selected Organic Compounds Containing Representative Functional Groups

The binary hydride, diisobutylaluminum borohydride [(iBu)2AlBH4], synthesized from diisobutylaluminum hydride (DIBAL) and borane dimethyl sulfide (BMS) has shown great potential in reducing a variety of organic functional groups. This unique binary hydride, (iBu)2AlBH4, is readily synthesized, versatile, and simple to use. Aldehydes, ketones, esters, and epoxides are reduced very fast to the corresponding alcohols in essentially quantitative yields. This binary hydride can reduce tertiary amides rapidly to the corresponding amines at 25 °C in an efficient manner. Furthermore, nitriles are converted into the corresponding amines in essentially quantitative yields. These reactions occur under ambient conditions and are completed in an hour or less. The reduction products are isolated through a simple acid-base extraction and without the use of column chromatography. Further investigation showed that (iBu)2AlBH4 has the potential to be a selective hydride donor as shown through a series of competitive reactions. Similarities and differences between (iBu)2AlBH4, DIBAL, and BMS are discussed.

1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS

The present invention relates to the 1 H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) osteoporosis, (viii) cardiac hypertrophy, (ix) epilepsies and (x) neuropathic pain.

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. For Formula (I) compounds R1, R2, X1, Y1 and n are as defined in the specification. The inventive Formula (I) compounds are inhibitors of the PD-1/PD-L1 protein/protein binding or functional interaction and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer and infectious diseases.

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.